Frankfurt
01.11.24
21:49 Uhr
2,050 Euro
-0,050
-2,38 %
-2,38 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NAVAMEDIC ASA: Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business | 1 | Cision News | ||
| Mo | Navamedic ASA: Invitation to 2024 3rd quarter presentation | 1 | Cision News | ||
| 07.10. | Navamedic ASA: Navamedic wins joint Nordic antibiotics tender | - | Oslo Børs | ||
| 19.09. | Navamedic ASA - Registration of share capital increase | 1 | Oslo Børs | ||
| 12.09. | Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson's Disease | 218 | PR Newswire | STOCKHOLM, Sept. 12, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has partnered with... ► Artikel lesen | |
| 09.09. | Navamedic ASA - Mandatory notification of trade by primary insider | - | Oslo Børs | ||
| 09.09. | NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS | 1 | Cision News | ||
| 21.08. | Navamedic ASA - Mandatory notice of trade | 1 | Oslo Børs | ||
| 16.08. | Navamedic ASA: Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement | 253 | PR Newswire | OSLO, Norway, Aug. 16, 2024 /PRNewswire/ -- In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies... ► Artikel lesen | |
| 12.08. | Navamedic ASA: Invitation to 2024 2nd quarter presentation | 1 | Cision News | ||
| 24.06. | Navamedic ASA: Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe | 269 | PR Newswire | OSLO, Norway, June 24, 2024 /PRNewswire/ -- Navamedic ASA and Orion Corporation ("Orion") have today signed a license and supply agreement for Flexilev®, including the OraFID® dispenser,... ► Artikel lesen | |
| 04.06. | Navamedic ASA: Minutes of Annual General Meeting | 449 | PR Newswire | OSLO, Norway, June 4, 2024 /PRNewswire/ -- The Annual General Meeting of Navamedic ASA was held today at 09:00 CEST. All items on the agenda were resolved in accordance with the board of... ► Artikel lesen | |
| 16.05. | Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals | 330 | PR Newswire | OSLO, Norway, May 16, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation... ► Artikel lesen | |
| 14.05. | Navamedic ASA: Notice of Annual General Meeting | 1 | Oslo Børs | ||
| 06.05. | Navamedic ASA: Broad launch for Eroxon® in Sweden today | 359 | PR Newswire | OSLO, Norway, May 6, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon®... ► Artikel lesen | |
| 23.04. | Navamedic ASA: Invitation to 2024 1st quarter presentation | 185 | PR Newswire | OSLO, Norway, April 23, 2024 /PRNewswire/ -- Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2024 results on Tuesday, April 30, 2024. The presentation will be held at Haakon... ► Artikel lesen | |
| 13.03. | Navamedic ASA: Navamedic welcomes new shareholders | 660 | PR Newswire | OSLO, Norway, March 13, 2024 /PRNewswire/ -- Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø... ► Artikel lesen | |
| 13.03. | Navamedic ASA: Notification of major shareholding and mandatory notification of trade | 495 | PR Newswire | OSLO, Norway, March 12, 2024 /PRNewswire/ -- Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the Nordic pharmaceutical company Navamedic ASA. The shares were... ► Artikel lesen | |
| 15.02. | Navamedic ASA: Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives | 343 | PR Newswire | OSLO, Norway, Feb. 15, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced... ► Artikel lesen | |
| 13.02. | Navamedic ASA: Invitation to 2023 4th quarter presentation | 381 | PR Newswire | OSLO, Norway, Feb. 13, 2024 /PRNewswire/ -- Navamedic ASA (OSE: Nava) will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024. The presentation will be held at Dronning... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DERMAPHARM | 31,050 | -0,48 % | EQS-DD: Dermapharm Holding SE: Susanne Gertrud Pia Lanz, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
23.10.2024 / 16:32... ► Artikel lesen | |
| MPH HEALTH CARE | 23,800 | 0,00 % | MPH Health Care Aktie: Solide Entwicklung im Gesundheitssektor | Die MPH Health Care AG verzeichnet eine positive Entwicklung im Gesundheitsmarkt. Der Aktienkurs liegt aktuell bei 24,60 EUR und konnte im vergangenen Monat um 4,68% zulegen. Besonders bemerkenswert... ► Artikel lesen | |
| CRONOS GROUP | 1,886 | -5,65 % | Cronos Group Inc: Cronos Group to hold Q3 2024 results call Nov. 12 | ||
| ORGANIGRAM | 1,600 | -0,12 % | Paolo De Luca Sells 12,014 Shares of Organigram Holdings Inc. (TSE:OGI) Stock | ||
| GRIFOLS | 10,495 | +0,19 % | Berenberg Bank Upgrades Grifols (NASDAQ:GRFS) to Strong-Buy | ||
| APONTIS PHARMA | 9,720 | -0,41 % | APONTIS PHARMA: Annahme des öffentlichen Übernahmeangebots von Zentiva empfohlen | Vorstand und Aufsichtsrat der APONTIS PHARMA AG, einem führenden deutschen Anbieter von Single Pill-Kombinationen, haben heute eine gemeinsame Stellungnahme zum öffentlichen Übernahmeangebot der Zentiva... ► Artikel lesen | |
| PHARMASGP | 24,600 | 0,00 % | PharmaSGP Holding Aktie: Starke Kursentwicklung und hohe Dividendenrendite | ||
| BACHEM | 74,15 | 0,00 % | Bachem startet langsam ins Jahr 2024 | Bubendorf - Das Biochemie-Unternehmen Bachem hat im ersten Halbjahr 2024 eine Spur mehr umgesetzt und etwas mehr verdient. Gleichzeitig treibt der Pharmazulieferer den Ausbau der Organisation voran... ► Artikel lesen | |
| COSMO PHARMACEUTICALS | 72,50 | +2,11 % | Cosmo Pharmaceuticals N.V.: Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM | Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") shareholders today approved the proposal by the Board of Directors to appoint Deloitte... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 291,10 | -0,38 % | West Pharmaceutical Services Aktie: Zukunftsplan mit Erfolg | West Pharmaceutical Services, Inc. hat mit seinen jüngsten Quartalszahlen die Erwartungen übertroffen und damit für Aufsehen an der Börse gesorgt. Der Aktienkurs des Medizintechnikunternehmens reagierte... ► Artikel lesen | |
| AZENTA | 38,200 | 0,00 % | Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test | BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for... ► Artikel lesen | |
| POLYPEPTIDE GROUP | - | - | PolyPeptide-Aktie aufgewertet: RBC sieht Potenzial für Verdreifachung des Kurses | ||
| PHOTOCURE | 4,240 | +0,47 % | Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting | OSLO, Norway, Sept. 30, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 1,410 | -2,08 % | ArcticZymes Technologies ASA: Invitation to presentation of Q3 and 9M 2024 results | ||
| ULTIMOVACS | 0,128 | 0,00 % | Ultimovacs ASA: Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv |
Das Unternehmen NAVAMEDIC ASA kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,050 (-2,38 %) liegt der Kurs bei 2,050 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NAVAMEDIC ASA finden Sie auf Wallstreet Online.
